ReviewFrontiers in oncology2022

Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors.

Xiangchen Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.